Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.

Hazra R, Cohen RA, Gonin R, Monteiro JP, Hofer CB, Negra MD, Ruz NP; NISDI Pediatric Study Group 2011.

AIDS. 2012 Jan 14;26(2):235-40. doi: 10.1097/QAD.0b013e32834dc5fc.

PMID:
22008654
2.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
3.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
4.

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team.

BMC Infect Dis. 2005 Jan 12;5:2.

5.

Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

Lu CL, Lin YH, Wong WW, Lin HH, Ho MW, Wang NC, Hsieh SM, Sheng WH, Hung CC, Chen MY.

J Microbiol Immunol Infect. 2011 Aug;44(4):258-64. doi: 10.1016/j.jmii.2010.08.003. Epub 2011 Jan 20.

6.

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.

Calza L, Manfredi R, Farneti B, Chiodo F.

Int J Antimicrob Agents. 2003 Jul;22(1):54-9.

PMID:
12842328
7.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
8.

Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy.

Tremeschin MH, Sartorelli DS, Cervi MC, Negrini BV, Salomão RG, Monteiro JP.

Rev Soc Bras Med Trop. 2011 May-Jun;44(3):274-81. Epub 2011 Jul 1.

9.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
10.

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V.

Circulation. 1999 Aug 17;100(7):700-5.

11.

Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

Calza L, Manfredi R, Chiodo F.

Infection. 2002 Jan;30(1):26-31.

PMID:
11876511
12.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(5):585-91.

PMID:
16152752
13.

Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.

Hiransuthikul N, Hiransuthikul P, Kanasook Y.

Southeast Asian J Trop Med Public Health. 2007 Jan;38(1):69-77.

PMID:
17539249
15.

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM.

J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):92-8. Review.

PMID:
15573713
16.
17.

Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.

Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):594-600.

PMID:
12902803
18.

First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.

Liu E, Armstrong C, Spiegelman D, Chalamilla G, Njelekela M, Hawkins C, Hertzmark E, Li N, Aris E, Muhihi A, Semu H, Fawzi W.

Clin Infect Dis. 2013 Jun;56(12):1820-8. doi: 10.1093/cid/cit120. Epub 2013 Feb 28.

PMID:
23449270
19.

Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.

Livingston EG, Cohn SE, Yang Y, Watts HD, Bardeguez AD, Jones TB, Smith LM, Umbleja T, McComsey GA.

Obstet Gynecol. 2007 Aug;110(2 Pt 1):391-7.

PMID:
17666616
20.

Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis.

Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, Bulterys M; Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):453-60.

PMID:
16652053

Supplemental Content

Support Center